September 24, 2024 06:35 PM EDT
R&D

Am­gen re­ports dual Phase 3 wins in atopic der­mati­tis and myas­the­nia gravis

Max Gelman

Senior Editor

Am­gen re­leased da­ta from two piv­otal tri­als on Tues­day that showed its ex­per­i­men­tal drug ro­catin­limab suc­ceed­ed in a Phase 3 test in atopic der­mati­tis, while …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times